CTIC-Cell Therapeutics, Inc.-Penny Stock-Biotechnology - Stock Market Forum, Penny Stocks, FOREX, NASDAQ, AMEX, NYSE, Live Chat

Weirdharold · #1 08-16-2007, 12:47 AM

This is one that news was released on just a few minutes ago... I have no idea how this one's T/A looks, but thought I might call it to your attention.

CTIC Overview
Name: CELL THERAPEUTICS INC
Address: 501 Elliott Avenue West, Suite 400 Seattle, WA, US
Telephone: (206) 282-7100 Website: www.cticseattle.com
Facsimile: (206) 284-6206 Email: investors.italia@ctimilano.com
Business Description: The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.
Details
CEO: Dr.James A. Bianco, M.D.
Employees: 197
Issue Type: CS
Market Cap: 155564626
Auditor: Stonefield Josephson, Inc.
Last Audit: UQ
Industry Classifications
Sector: HEALTHCARE NAICS: Pharmaceutical Preparation Manufacturing
Industry: Drug Manufacturers - Other CIK: 0000891293
SIC: PHARMACEUTICAL PREPARATIONS (2834)
Profitability Management Effectiveness
Gross Margin: NC Return on Equity: NE
EBIT Margin: NC Return on Capital: -200.3
Profit Margin: NC Return on Assets: -115.2
Share Statistics
Outstanding: 43332765 Float: 43066225
Short Interest: 1688345 as of (2007/07/10)
Short Int Ratio: 5.7 % of Float: 3.9
Non-Corp. Insider Hold'gs: 0.6% as of (2007/07)
Bought Prev 3 Mo: 3125 Sold Prev 3 Mo: 1450
Institution Hold'gs: 6.6% as of (2007/07)
Total Held: 2850527 Institutions: 46
Bought Prev Mo: 553061 Sold Prev Mo: 59449

Weirdharold · #2 08-16-2007, 12:47 AM

Here is the press release.

Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Acquisition of Lymphoma Drug Zevalin(R) from Biogen Idec
Aug 16, 2007 12:15:00 AM
SEATTLE, Aug. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTAX: CTIC) (CTI) will host a conference call today (Thursday, August 16) at 8:30 a.m. Eastern to discuss the acquisition of Zevalin from Biogen Idec. The conference call and slides will be web cast live and archived approximately two hours after the conference call ends.

Conference Call Numbers
Thursday, August 16
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific
866-249-6463
303-262-2211

Webcast and slides available at
http://www.cticseattle.com --
webcast will be archived approximately two hours after call ends.

Call-back numbers for post listening available at 10:00 am Eastern
800-405-2236
303-590-3000
Passcode: 11095845

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
Susan Callahan
T: 206.272.4472
F: 206.272.4434
E: media@ctiseattle.com
http://www.cticseattle.com/media.htm

Investors Contact:
Leah Grant
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
http://www.cticseattle.com/investors.htm
SOURCE Cell Therapeutics, Inc.

----------------------------------------------
Media
Dan Eramian
+1-206-272-4343
cell
+1-206-854-1200
or Susan Callahan
+1-206-272-4472
media@ctiseattle.com
Investors
Leah Grant
+1-206-282-7100
invest@ctiseattle.com
all of Cell Therapeutics
Inc.
fax
+1-206-272-4434

Weirdharold · #3 08-16-2007, 12:51 AM

Got these backward but you get the idea!

Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
CTI to host conference call to discuss the acquisition
Aug 16, 2007 12:01:00 AM
SEATTLE, Aug. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTAX: CTIC) (CTI) announced today that it has agreed to acquire Zevalin(R) (ibritumomab tiuxetan), the first FDA-approved radioimmunotherapy, from Biogen Idec. CTI will be responsible for marketing, sales, and development of the drug in the United States. The drug will continue to be sold outside the United States by Bayer Schering under an agreement between Biogen Idec and Bayer Schering. The U.S. Food and Drug Administration (FDA) approved Zevalin in 2002 to treat patients with relapsed indolent non-Hodgkin's lymphoma (NHL). In 2006, Biogen Idec reported $16.4 million in U.S. Zevalin sales. CTI will host a conference call today at 8:30 a.m. Eastern to discuss the acquisition.

"Zevalin is an effective yet underutilized drug with a favorable tolerability profile, producing high rates of complete response coupled with long-term remissions, all following just a single therapeutic dose," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "We believe the potential cost savings and practice efficiencies compared to standard combination chemotherapy will become increasingly attractive to oncology group practices in the ever-evolving reimbursement environment. We are currently planning to conduct registration-directed trials to expand the label into first-line treatment in both the aggressive and indolent NHL settings," Singer noted.

"Acquiring Zevalin returns CTI to a select group of biotech companies who market and sell a commercial product in the United States. We see potential for substantial revenue growth for this product with additional clinical data and increased patient and physician knowledge about its potential in treating patients with NHL," said James A. Bianco, M.D., President and CEO of CTI. "Importantly, in addition to the untapped revenue potential for Zevalin, it is an excellent complement to pixantrone, which is in phase III trials in similar patient populations. Ensuring this important cancer treatment remains available to patients fits into CTI's mission of making cancer more treatable."

Under the terms of the agreement, CTI will assume control of U.S. marketing, sales, and development of Zevalin. Upon closing, CTI has agreed to pay Biogen Idec $10 million in cash up front, up to an additional $20 million in milestone payments when the product receives approval for a first-line indication in NHL, and royalties on sales. CTI has also agreed to share the cost of certain clinical trials of Zevalin with Bayer Schering in the event such trials are undertaken. The acquisition is subject to certain closing conditions, including filings under the Hart-Scott-Rodino Antitrust Improvements Act. CTI was advised on the transaction by CIBC World Markets Corp.

The anticipated acquisition marks the second of two steps CTI has taken to strengthen its product pipeline and re-establish its commercial presence. On July 31, CTI completed the acquisition of Systems Medicine, Inc. (SMi), which provides CTI with worldwide rights to Brostallicin, a late-stage DNA minor groove binding agent with proven anti-tumor activity and a favorable safety profile in more than 200 patients treated to date in clinical trials. Brostallicin is currently in phase II clinical studies. In anticipation of its re-entry into the market with a commercialized product, CTI has plans to hire an industry veteran with strong experience in oncology drug development to lead its commercial operations.

About Zevalin(R)

Zevalin(R) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (RITUXAN) infusions. Yttrium-90 ZEVALIN administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the ZEVALIN therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to ZEVALIN therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). ZEVALIN should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for
more information.
About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the SEER CanQuest Database and the American Cancer Society, in 2005 the prevalence of indolent NHL in the U.S. was 282,025 with 24,490 newly diagnosed patients. The prevalence of aggressive NHL in the U.S. was 99,880 with 31,900 newly diagnosed patients.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplified administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

Conference Call Details
Thursday, August 16
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific
866-249-6463
303-262-2211
Webcast and slides available at

http://www.cticseattle.com - webcast will be archived approximately two hours after call ends.

Call-back numbers for post listening available at 10:00 a.m. Eastern, ending August 23:

800-405-2236
303-590-3000
Passcode: 11095845
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone and Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone and Zevalin in particular including, without limitation, the potential failure of pixantrone and Zevalin to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone and Zevalin. In addition, there is a risk that we may not be able to complete the acquisition of Zevalin due to closing conditions, or that we may not recognize the full expected value of Zevalin in future years. In addition, you should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
Susan Callahan
T: 206.272.4472
F: 206.272.4434
E: media@ctiseattle.com
http://www.cticseattle.com/media.htm

Investors Contact:
Leah Grant
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
http://www.cticseattle.com/media.htm

Medical Information Contact:
Zevalin Customer Care
T: 866.298.8433
SOURCE Cell Therapeutics, Inc.

----------------------------------------------
media
Dan Eramian
+1-206-272-4343
cell
+1-206-854-1200
or Susan Callahan
+1-206-272-4472
fax
+1-206-272-4434
media@ctiseattle.com; or investors
Leah Grant
+1-206-282-7100
fax
+1-206-272-4434
invest@ctiseattle.com; or medical information
Zevalin Customer Care
+1-866-298-8433
all for Cell Therapeutics
Inc.

sg1efc · #4 07-11-2008, 01:52 PM

Don't know much about this company but their stock is at 52 week low:

Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Monday July 7, 1:30 am ET
Results are basis for CTI's Marketing Authorization Application currently under review by the EMEA

SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today announced the publication of results from its randomized phase III trial comparing OPAXIO(TM) (paclitaxel poliglumex, CT-2103) with gemcitabine or vinorelbine for the treatment of PS 2 (performance status 2) patients with previously untreated non-small cell lung cancer (NSCLC) in the Journal of Thoracic Oncology (Volume 3, Number 7, July 2008). Results showed that overall survival was similar between the two arms (hazard ratio of 0.95; OPAXIO to control). Patients treated with OPAXIO required less supportive care including fewer red blood cell transfusions, hematopoietic growth factors, and opioid analgesics than those patients receiving either gemcitabine or vinorelbine. There were relatively few non-hematopoietic grade 3 or 4 toxicities in either arm. Additionally, patients receiving OPAXIO required fewer clinic visits due to its administration schedule, once every three weeks, and short infusion time, compared to patients receiving either gemcitabine or vinorelbine.

The objective of the study, known as STELLAR 4, was to determine if OPAXIO would improve overall survival when compared with the standard single-agent treatments of gemcitabine or vinorelbine in PS 2 patients with advanced NSCLC who had not previously received chemotherapy. The trial did not meet the primary endpoint. Secondary objectives of the study included measuring the efficacy and safety of the treatments. OPAXIO did demonstrate similar overall survival and a reduction in the supportive care required by patients.

A total of 190 patients with advanced NSCLC were randomized to the comparator arm; 191 were randomized to the OPAXIO arm with a dosage of 175 mg/m^2, and 96 were randomized to the OPAXIO arm at a dosage of 235 mg/m^2. The OPAXIO dose was reduced to 175 mg/m^2 after 96 patients had been treated, because the Data Monitoring Committee noted an increase in deaths associated with neutropenia in patients who had received the 235 mg/m^2 dosage. The following data refers to those patients treated at the OPAXIO dose of 175 mg/m^2. The median number of cycles administered was 4, with a median of 3.5 in the control arm. A total of 754 cycles of OPAXIO were administered, and 652 cycles were administered in the comparator arm. More patients in the OPAXIO arm received 6 cycles of treatment (38 percent versus 23 percent; p = 0.002). Progressive disease was the most common reason for not completing 6 cycles (55 percent in the OPAXIO arm and 59 percent in the comparator arm). Fewer OPAXIO patients (12 percent) discontinued treatment as a result of adverse events, compared to 17 percent of patients in the control arm. Survival, time to progression (TTP), and response rates were similar in both arms. Median overall survival was 7.3 months in the OPAXIO arm and 6.6 months in the control arm. The estimated 1-year survival rate was the same in both arms (26 percent), and the approximate 2-year survival rate was numerically higher in the OPAXIO arm (15 percent) than the comparator arm (10 percent). There was a lower requirement for red blood cell transfusions (p = 0.001), erythropoietin use (p = 0.014), myeloid growth factors (p = 0.032), and new narcotic analgesics (p = 0.034) in the OPAXIO arm when compared to the control arm. No significant differences were evident in quality of life based on FACT-LCS evaluations between the two arms. OPAXIO patients experienced fewer hematologic (p <0.001) and gastrointestinal (p = 0.004) adverse events. Neuropathy occurred more frequently in the OPAXIO arm compared with the control arm (30 percent versus 5 percent, (p <0.001)), and grade 3 neuropathy occurred in 4 percent of the OPAXIO patients, with no occurrences of grade 4 neuropathy. There was a lower incidence of alopecia in the OPAXIO arm (2 percent versus 5 percent respectively, p = 0.085), as well as fatigue (16 percent versus 25 percent, p= 0.055), asthenia (11 percent versus 16 percent, p = 0.169), and weight loss (7 percent versus 12 percent, p = 0.121).

Details of the Study

The phase III trial, reported by Mary E. R. O'Brien, M.D., F.R.C.P., et al, of the Royal Marsden Hospital and the Kent Cancer Centre in Surrey, UK, was a randomized, multi-center trial. The trial was conducted at 83 centers in ten countries, and randomized on a 1:1 ratio to evaluate the efficacy and safety of this regimen in patients with chemotherapy-naïve NSCLC. Patients with advanced stage IIIb/IV NSCLC and PS 2 were treated with OPAXIO on day 1 of a 21-day cycle, while patients receiving gemcitabine were treated on days 1, 8, and 15 of each 28-day cycle. Vinorelbine was administered on days 1, 8, and 15 of each 21-day cycle. Patients received up to six cycles of treatment, and were not treated until significant toxicities were under control (less than or equal to grade 1). The primary objective was effect on survival, and secondary objectives were determining the efficacy and safety of the treatments.

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was previously branded as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, paclitaxel is rendered inactive, potentially sparing normal tissue's exposure to high levels of the active drug and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies. This is being studied in an ongoing phase III trial.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics Cancer Research, Cancer Therapies, and Cancer Drug Development Home Page.

**Paul** · #5 01-27-2009, 11:36 AM

i picked up 10k of ctic today. hoping it does a nice profitable run

Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Tuesday January 27, 1:30 am ET

SEATTLE, Jan. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that after communication with the Food and Drug Administration (FDA), CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non-Hodgkin's lymphoma (NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.

"This communication from the FDA is a significant milestone for the Company and for patients with relapsed aggressive NHL as this could be the first drug approved for this unmet medical need," noted James A. Bianco, M.D. Chief Executive Officer of CTI. "With the potential for three drug approvals in 2009 we are on track to meet our objective of cash flow break even in the fourth quarter of this year."

The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). CR/uCR and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.

The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..

**Paul** · #6 01-27-2009, 05:37 PM

after hours is 12x125. last trade .12. i sold all my stem at a nice profit and bought ctic at .098 and .11. i am all smiles

**Paul** · #7 01-27-2009, 07:02 PM

as most of you know i do not do research on stocks if they are penny stocks and by penny stocks i mean stinky pinky's and otcbb stocks. ctic is naz. take a close look at ctic. april 2007 was trading at over $67.00 a share. the 1 year target is $50.00 a share. been bounced of the all time low of a nickle and is poised for a nice run in my opinion. people i think we have a winner here

. if i had researched this more i would have bought a whole lot more then i did. i got around 12,000 shares today. i will probably get more pre market tomorow.

now trading at .13 after hours

Ericp501 · #8 01-27-2009, 07:09 PM

The volume is nutts!

**Paul** · #9 01-27-2009, 07:34 PM

been a long time since i seen after hours volume like this

**Klipper22** · #10 01-28-2009, 12:03 AM

stockmarkettiming.com posted this as their pick for tomorrow. I do not really know anything about them, but I do know that Tina will do everything that she can to spread it all over IFLUB. A friend of mine just told me that she was posting about it. It is a solid play (that's why I mentioned it this morning), IMO, but it never hurts to know if the momo players and pumpers are going to be jumping in. I think some solid green will be coming fast, just also trying to exercise a word of caution and a reminder to take some off when it is available. Check the slogan above.